Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|May 18, 2006
Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphomaKevin W Song, Michael J Barnett, Randy D Gascoyne, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2018
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted AnalysisWasithep Limvorapitak, Michael J Barnett, Donna E Hogge, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill, John D Shepherd, Heather J Sutherland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2006
Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomesK W Song, M J Barnett, R D Gascoyne, et al.
Leukemia Research|September 3, 2008
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levelsDonna L Forrest, Shannon Trainor, Ryan R Brinkman, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Bone Marrow Transplantation|August 6, 2008
Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AMLT J Nevill, D E Hogge, C L Toze, et al.
Stem Cell Reviews and Reports|June 5, 2025
Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre ExperienceJowon L Kim, Moss A Bruton Joe, Shanee Chung, et al.
Blood|May 5, 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie, Joseph M Connors, Gordon L Phillips, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
Pageof 8